Toralizumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
TargetCD40 ligand
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
 ☒NcheckY (what is this?)  (verify)

Toralizumab (IDEC 131) was a humanized monoclonal antibody and an immunosuppressive drug. Possible indications included treatment of antibody-mediated disorders (immune thrombocytopenic purpura, lupus nephritis, rheumatoid arthritis), T-cell-mediated diseases (multiple sclerosis, Crohn's disease, and transplantations such as solid organ transplantation, pancreatic islet cell transplantation, and corneal transplantation), and B-cell malignancies such as CLL/small lymphocytic lymphoma, follicular cell lymphoma grade I or II, marginal zone lymphoma, mantle cell lymphoma, MALT lymphoma, Waldenström's macroglobulinemia, monocytoid B-cell lymphoma; relapsed/refractory Hodgkin's disease).[1]

In Phase II clinical trials regarding multiple sclerosis and Crohn's disease, thromboembolisms occurred in at least three patients. A causal connection could not be proven, but since the same adverse effects were seen in trials with a similar antibody (hu5C8), the trials were halted.[2]

The drug was developed by IDEC Pharmaceuticals Corporation.

References

  1. ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Toralizumab, American Medical Association.
  2. ↑ Luebke RW, House RV, Kimber I (2007). Immunotoxicology and immunopharmacology. Target Organ Toxicology Series (3rd ed.). Boca Raton, Florida: CRC Press, Taylor & Francis Group. p. 131. ISBN 978-0-8493-3790-1.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.